Who invested in Aligos Therapeutics

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$105Mraised across 1 round since 2025, from 1 source

Latest round: Round, $105MFeb 2025
Investors: 5

See who backed them

The rounds

Feb 2025
Round$105M
Source recordedSEC filing: $105M sold, first sale Feb 2025

Founders and team

From Aligos Therapeutics's own website: 13 on the team.

Lawrence M. BlattChairman, President, & Chief Executive Officer
Rámon PoloSenior Vice President, Head of Global Regulatory Affairs
Bridget MartellDirector
Carole NuechterleinDirector
Heather PrestonDirector
J.d. M.b.a.Director
K. Peter HirthDirector
Margarita ChavezDirector
David B. SmithTeam
Julian SymonsTeam
Lesley Ann CalhounTeam
Sushmita M. ChandaTeam
Tse-I LinTeam

Everyone who backed them

Wellington ManagementVC firm1round

Novo HoldingsVC firm1round

Janus Henderson InvestorsPrivate equity1round

Cormorant Asset ManagementPrivate equity1round

Vivo CapitalPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Aligos Therapeutics

Who invested in Aligos Therapeutics?

Aligos Therapeutics's investors include Wellington Management, Novo Holdings, Janus Henderson Investors, Cormorant Asset Management and Vivo Capital.

How much has Aligos Therapeutics raised?

Aligos Therapeutics has raised $105M across 1 round since 2025.

When did Aligos Therapeutics last raise?

Aligos Therapeutics's most recent round was an Undisclosed round of $105M in Feb 2025.

What was Aligos Therapeutics's biggest round?

Its most recent round, $105M in Feb 2025, is also its largest on record.

Who backed Aligos Therapeutics first?

Aligos Therapeutics's first round on record, in Feb 2025, was backed by Wellington Management, Novo Holdings and Janus Henderson Investors and 2 others.